For research use only. Not for use in humans.

Donanemab (Anti-Amyloid Beta)

Synonyms: LY3002813 Cat.No.A2833 Purity:99%

Donanemab (LY3002813) is a humanised IgG1 monoclonal antibody directed at an N-terminal pyroglutamate Beta Amyloid (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW: 145.36 KD.

Quality Control

Batch: Purity: 99% Protein concentration: 9.27mg/ml Endotoxin Level: ＜1EU/mg

Specificity

Name	Citation	Beta Amyloid	Others
DAPT	398	++
RO4929097 (RG-4733)	124	+++	γ secretase,γ secretase(ICN)
MK-0752	23	+++
Avagacestat (BMS-708163)	22	++++
LY2811376	19	+	BACE1
Tabersonine hydrochloride	0	✔
EUK 134	6	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Donanemab (LY3002813) is a humanised IgG1 monoclonal antibody directed at an N-terminal pyroglutamate Beta Amyloid (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW: 145.36 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/33720637/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1931944-80-7
Molecular Weight	145.36
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.